Type 2 diabetes mellitus or impaired glucose tolerance
Conditions
Interventions
Glucose solution 50 g as the reference diet will be ingested and blood glucose level up to 3 hours after ingestion will be measured to have an area under the blood glucose concentration profile (AUC).
Sponsors
InCROM Inc.
Medical Corporation Heishinkai ToCROM Clinic InCROM Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Subjects who give voluntary consent to participate in the study after they fully understand the explanations on the objective, procedure, duration, and foreseeable disadvantages of the study (2) Subjects aged 20 years or older and have diagnosed type 2 diabetes or impaired glucose tolerance, or have these status suspected from previous tests (3) Subjects who are able to follow the study doctor's instructions and report subjective symptoms
Exclusion criteria
Exclusion criteria: (1) Present or history of hepatic disorder, renal disorder, cardiovascular disease, respiratory disease, endocrine system disease, metabolic disease, neurological disease, or psychiatric disease which is not relevant for enrollment in the study as determined by the principal investigator or sub-investigator during the pre-study examinations (2) Present or history of serious allergy or hypersensitivity (3) Known allergic symptoms or aggravation of such symptoms when consuming sugar or a similar product (4) Present or history of drug or alcohol dependence (5) Medical treatment for diabetes with: a) insulin b) GLP-1 receptor agonist, or c) thiazolidine compound (6) Medical treatment for diabetes with 2 or more medications (7) Blood glucose level exceeding 200 mg/dL by self-measured glucometer before ingest of the reference diet (8) Other subjects who are not eligible for the study as determined by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GI levels of superfine sugar and fructose computed when glucose solution 50 g/150 mL is ingested as the reference diet | — |
Countries
Japan
Contacts
Public ContactHisayoshi Daito
Medical Corporation Heishinkai OCROM Clinic Director
Outcome results
None listed